Drugs / Emiltatug Ledadotin
Emiltatug Ledadotin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05377996 | Aug 2022 → Feb 2027 expected | adenoid cystic carcinoma, endometrial cancer, fallopian tube cancer, ovarian cancer +2 | Day One Biopharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emiltatug Ledadotin | “A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors” NCT05377996 ↗ |
| Known as | Emi-Le | “A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors” NCT05377996 ↗ |
| Known as | Emiltatug ledadotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068119 ↗ |
| Known as | Emiltatug ledadotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068119 ↗ |
| Known as | XMT-1660 | “This first-in-human (FIH) study will test the safety, side effects, and antitumor activity of a drug called Emi-Le ((Emiltatug Ledadotin, formerly XMT-1660).” NCT05377996 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068119 ↗ |
| Route | Intravenous | “Emi-Le will be administered through a vein in your arm or port catheter (intravenously)” NCT05377996 ↗ |